Login to Your Account

Adocia Raises €14M to Boost Protein Chaperone Technology

By Cormac Sheridan

Wednesday, January 13, 2010

No Abstract


BioWorld International Correspondent


Adocia SA raised €14 million (US$20.3 million) in a second funding round to continue development of its BioChaperone protein delivery technology, which is designed to prolong the localized activity of growth factors and other protein-based drugs at their sites of action. The company, based in Lyon, France, has filed investigational new drug applications on its first two development programs, and clinical trials are due to begin shortly.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription